Dr. Dummer on Driver Mutations and Next Steps in Melanoma

Reinhard Dummer, MD
Published: Thursday, Sep 15, 2016



Reinhard Dummer, MD, professor, Department of Dermatology, University of Zurich Hospital, discusses driver mutations and next steps in the treatment of patients with melanoma.

There are several melanoma subtypes based on driver mutations in the MAP kinase pathway. Most of them are mutated for BRAF, and while there are several medications for those types of mutations, there is a huge medical need for specific treatments of NRAS mutations, says Dummer.

The NEMO trial, which randomly assigned patients to receive the combination of the MEK inhibitor binimetinib and dacarbazine or dacarbazine alone, demonstrated binimetinib's potential as an alternative treatment option for patients with NRAS-mutant melanoma. This is a good first step in this setting, says Dummer, but there is certainly room for improved outcomes in future studies.
SELECTED
LANGUAGE


Reinhard Dummer, MD, professor, Department of Dermatology, University of Zurich Hospital, discusses driver mutations and next steps in the treatment of patients with melanoma.

There are several melanoma subtypes based on driver mutations in the MAP kinase pathway. Most of them are mutated for BRAF, and while there are several medications for those types of mutations, there is a huge medical need for specific treatments of NRAS mutations, says Dummer.

The NEMO trial, which randomly assigned patients to receive the combination of the MEK inhibitor binimetinib and dacarbazine or dacarbazine alone, demonstrated binimetinib's potential as an alternative treatment option for patients with NRAS-mutant melanoma. This is a good first step in this setting, says Dummer, but there is certainly room for improved outcomes in future studies.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x